Development of a model for the differential diagnosis of community-acquired bacterial pneumonia and viral lung injury in hospitalized adult patients

Relevance. During and after the COVID-19 pandemic, viruses have become a more common cause of pulmonary infections in adults; therefore, the distinction between viral lung injury and community-acquired bacterial pneumonia is of increasing importance. Aim. Development of a model for differentiating community-acquired bacterial pneumonia and viral lung injury, including COVID-19. Materials and methods. This retrospective case–control study included 300 adult patients with viral lung injury and 100 adult patients with community-acquired bacterial pneumonia. Clinical, laboratory, and instrumental data were analyzed, significant factors were selected by which the samples differed, and a model was developed using logistic regression to distinguish between community-acquired bacterial pneumonia and viral lung damage, including COVID-19. Results. The developed model included the following parameters: total protein level, neutrophil/lymphocyte index, heart rate, unilateral infiltration on CT or chest x-ray, vasopressor prescription in the first 24 h of hospitalization, altered level of consciousness, chills, and fatigue. The model had the following characteristics: AUC = 0.94 (0.92–0.96), AUC_PR = 0.84 (0.76 to 0.92), prediction accuracy — 90%, sensitivity — 76%, specificity — 95%, positive predictive value — 83 %. Conclusion. The use of this model can facilitate the differential diagnosis of community-acquired bacterial pneumonia and viral lung injury, including COVID-19, in adults in general wards and intensive care units.

1. Ankert J, Hagel S, Schwarz C, et al. Streptococcus pneumoniae re-emerges as a cause of community-acquired pneumonia, including frequent co-infection with SARS-CoV-2, in Germany, 2021. ERJ Open Res. 2023 May 30;9(3):00703-2022. doi: 10.1183/23120541.00703-2022.

2. Yan Y, Tomooka K, Naito T, Tanigawa T. Decreased number of inpatients with community-acquired pneumonia during the COVID-19 pandemic: A large multicenter study in Japan. J Infect Chemother. 2022;28(5):709-713. doi: 10.1016/j.jiac.2022.01.013.

3. Strelkova DA, Kupriushina OA, Yasneva AS et al. Differential diagnosis of community-acquired bacterial pneumonia and viral lung injury in hospitalized adults. Clinical Microbiology and Antimicrobial Chemotherapy (in press). (In Russ.).

4. Kamat IS, Ramachandran V, Eswaran H, et al. Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis. Clin Infect Dis. 2020 Jan 16;70(3):538-542. doi: 10.1093/cid/ciz545.

5. Ono A, Okada F, Takata S, et al. A comparative study of thin-section CT findings between seasonal influenza virus pneumonia and Streptococcus pneumoniae pneumonia. Br J Radiol. 2014 Jul;87(1039):20140051. doi: 10.1259/bjr.20140051.

6. Tian J, Xu Q, Liu S, et al. Comparison of clinical characteristics between coronavirus disease 2019 pneumonia and community-acquired pneumonia. Curr Med Res Opin. 2020 Nov;36(11):1747-1752. doi: 10.1080/03007995.2020.1830050.

7. Serrano Fernandez L, Ruiz Iturriaga LA, Espana Yandiola PP, et al. Bacteraemic pneumococcal pneumonia and SARS-CoV-2 pneumonia: differences and similarities. Int J Infect Dis. 2022 Feb;115:39-47. doi: 10.1016/j.ijid.2021.11.023.

8. Zhou Y, Guo S, He Y, et al. COVID-19 Is Distinct From SARS-CoV-2-Negative Community-Acquired Pneumonia. Front Cell Infect Microbiol. 2020 Jun 16;10:322. doi: 10.3389/fcimb.2020.00322.

9. Miyashita N, Nakamori Y, Ogata M, et al. Clinical Differences between Community-Acquired Mycoplasma pneumoniae Pneumonia and COVID-19 Pneumonia. J Clin Med. 2022 Feb 12;11(4):964. doi: 10.3390/jcm11040964.

10. Liu KC, Xu P, Lv WF, et al. Differential diagnosis of coronavirus disease 2019 from community-acquired-pneumonia by computed tomography scan and follow-up. Infect Dis Poverty. 2020 Aug 26;9(1):118. doi: 10.1186/s40249-020-00737-9.

11. Zhou J, Liao X, Cao J, et al. Differential diagnosis between the coronavirus disease 2019 and Streptococcus pneumoniae pneumonia by thinslice CT features. Clin Imaging. 2021 Jan;69:318-323. doi: 10.1016/j.clinimag.2020.09.012.

12. Mason CY, Kanitkar T, Richardson CJ, et al. Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics. J Antimicrob Chemother. 2021 Apr 13;76(5):1323-1331. doi: 10.1093/jac/dkaa563.

13. Song L, Liang EY, Wang HM, et al. Differential diagnosis and prospective grading of COVID-19 at the early stage with simple hematological and biochemical variables. Diagn Microbiol Infect Dis. 2021 Feb;99(2):115169. doi: 10.1016/j.diagmicrobio.2020.115169.

14. Wang J, Zheng Y, Chen Y, et al. Laboratory indicators in COVID-19 and other pneumonias: Analysis for differential diagnosis and comparison of dynamic changes during 400-day follow-up. Comput Struct Biotechnol J. 2021;19:2497-2507. doi: 10.1016/j.csbj.2021.04.063.

15. Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021 Apr;27(4):520-531. doi: 10.1016/j.cmi.2020.12.018.

16. Khan S, Hasan SS, Bond SE, et al. Antimicrobial consumption in patients with COVID-19: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2022 May;20(5):749-772. doi: 10.1080/14787210.2022.2011719.

17. Langford BJ, Soucy JR, Leung V, et al. Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis. Clin Microbiol Infect. 2023 Mar;29(3):302-309. doi: 10.1016/j.cmi.2022.12.006.

18. Lewandowski K, Rosołowski M, Kaniewska M, et al. Clostridioides difficile infection in coronavirus disease 2019 (COVID-19): an underestimated problem? Pol Arch Intern Med. 2021 Feb 26;131(2):121-127. doi: 10.20452/pamw.15715.